This company listing is no longer active
Initiator Pharma Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Wichtige Informationen
21.5%
Wachstumsrate der Gewinne
25.7%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 45.6% |
| Wachstumsrate der Einnahmen | 62.7% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | n/a |
Jüngste Aktualisierungen zum künftigen Wachstum
Keine Aktualisierungen
Recent updates
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2024 | 33 | -37 | -39 | -39 | 1 |
| 12/31/2023 | 106 | 44 | 51 | 51 | 1 |
| 12/31/2022 | N/A | -46 | -36 | -36 | 1 |
| 3/31/2022 | N/A | -34 | -40 | -40 | N/A |
| 12/31/2021 | N/A | -21 | -34 | -34 | N/A |
| 9/30/2021 | N/A | -16 | -29 | -29 | N/A |
| 6/30/2021 | N/A | -10 | -11 | -11 | N/A |
| 3/31/2021 | N/A | -8 | -10 | -10 | N/A |
| 12/31/2020 | N/A | -9 | -8 | -8 | N/A |
| 9/30/2020 | N/A | -10 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -9 | -7 | -7 | N/A |
| 3/31/2020 | N/A | -9 | -8 | -8 | N/A |
| 12/31/2019 | N/A | -8 | -9 | -9 | N/A |
| 9/30/2019 | N/A | -7 | -7 | -7 | N/A |
| 6/30/2019 | N/A | -9 | -7 | -7 | N/A |
| 3/31/2019 | N/A | -8 | -10 | -10 | N/A |
| 12/31/2018 | N/A | -10 | -14 | -14 | N/A |
| 9/30/2018 | N/A | -13 | -16 | -16 | N/A |
| 6/30/2018 | N/A | -11 | -14 | -14 | N/A |
| 3/31/2018 | N/A | -10 | -11 | -11 | N/A |
| 12/31/2017 | N/A | -9 | -8 | -8 | N/A |
| 9/30/2017 | N/A | -7 | -4 | -4 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: INIT BTA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Ertrag vs. Markt: INIT BTA is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hohe Wachstumserträge: INIT BTA is expected to become profitable in the next 3 years.
Einnahmen vs. Markt: INIT BTA's revenue (62.7% per year) is forecast to grow faster than the Swedish market (9.4% per year).
Hohe Wachstumseinnahmen: INIT BTA's revenue (62.7% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if INIT BTA's Return on Equity is forecast to be high in 3 years time